

**REMARKS**

Claims 1-9, 11, 20-33, 37-55 and 59-69 are pending.

Applicants elect with traverse Group I (claims 1-9, 11, 20-21, 28-33, 37-55, 59-60 and 68) and species SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35 for examination on the merits. Claims 1-4, 20-21, 28-32, 51-55, 59-60 and 68 read on the elected invention and species. Applicants reserve the right to prosecute nonelected subject matter in a further patent application.

In particular, the inventions listed as Groups I-V in the Action relate to a single general inventive concept. The special technical feature shared by the claims is an antibody or antibody fragment that can bind to the C-terminal domain of Apolipoprotein E (ApoE-CTD) and to human plaques. All of Groups I-V relate to the same genus of antibodies or antibody fragments. Their features are specifically recited in claim 1. But the antibodies or antibody fragments of the claims all have these properties, either explicitly or implicitly. This is clear from the Examples of Applicants' specification.

The Examiner no longer cites Cho *et al.* (J. Neuropathol. Exp. Neurolog. 60:342-349, 2001) in the pending Office Action as allegedly teaching a special technical feature of Applicants' invention. But if she will contend the cited reference teaches or suggests the claimed invention, the Examiner is requested to consider the comments thereon from the Response filed August 6, 2007.

Applicants earnestly solicit an early and favorable examination on the merits. The Examiner is invited to contact the undersigned if any further information is required

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_ /Gary R. Tanigawa/  
Gary R. Tanigawa  
Reg. No. 43,180

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100